Cognitive impairment, including decreased attention and memory, remains one of the most disabling aspects of schizophrenia, affecting social life of patients. However, no effective treatment has yet ...

Cognitive impairment, including decreased attention and memory, remains one of the most disabling aspects of schizophrenia, ...

OVERLAND PARK, KS, UNITED STATES, January 29, 2026 /EINPresswire.com/ -- NeuroDiscipline, a behavior-change framework ...

Mountain View, California Monday, February 16, 2026, 18:00 Hrs [IST] ...

A physician introduces a provocative theory linking informational overload and evolutionary mismatch to modern disease ...

Dementia is a sad fact of a dog’s twilight years as well.

In 2023, 9.8% of Louisiana seniors over the age of 65 reported having difficulty remembering, concentrating or making ...

In the recreation room at Eskaton Village in Carmichael, Bonnie Dale, one of the residents, is trying on a virtual reality ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the ...

Cognitive impairment, including decreased attention and memory, remains one of the most disabling aspects of schizophrenia, affecting social life of patients. However, no effective treatment has yet ...

Cognitive impairment, including decreased attention and memory, remains one of the most disabling aspects of schizophrenia, affecting social life of ...

SAGICO and its principals have achieved global success across more than 60 countries. The company operates through a privately held global network with an active pipeline of innovative products and ...